TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31578841

Group type: EXPERIMENTAL
Intervention: QFit (Quercetin Phytosome) + Standard Management (SM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Management (SM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: QFit (Quercetin Phytosome)
Number of subjects: 0
Study: 30010706

Group type: EXPERIMENTAL
Intervention: Integrated self-affirmation and implementation intentions
Number of subjects: 293

Group type: COMPARATOR
Intervention: Self-affirmation only
Number of subjects: 293

Group type: COMPARATOR
Intervention: Implementation intentions only
Number of subjects: 293

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 293
Study: 25336052

Group type: EXPERIMENTAL
Intervention: Laser scanning for ankle-foot orthoses production
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional plaster casting for ankle-foot orthoses production
Number of subjects: 0
Study: 24324048

Group type: EXPERIMENTAL
Intervention: Fixed combination of perindopril-indapamide (4/1.25 mg)
Number of subjects: 11140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11140
Study: 23231863

Group type: EXPERIMENTAL
Intervention: Assortment structure with 75% healthy snacks
Number of subjects: 250

Group type: COMPARATOR
Intervention: Assortment structure with 25% healthy snacks
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Shelf arrangement with healthy snacks at top shelves
Number of subjects: 250

Group type: COMPARATOR
Intervention: Shelf arrangement with healthy snacks at lower shelves
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Field study sales data
Number of subjects: 250
Study: 21148615

Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m² i.v. every 21 days until disease progression)
Number of subjects: 663

Group type: COMPARATOR
Intervention: Placebo plus best supportive care
Number of subjects: 663
Study: 17702126

Group type: EXPERIMENTAL
Intervention: Long-term peroral anticoagulation treatment for 6 to 12 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Three-month treatment period
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: D-dimer detection test
Number of subjects: 0
Study: 16779201

Group type: EXPERIMENTAL
Intervention: Web-based computer-assisted education (CO-ED) system
Number of subjects: 22

Group type: COMPARATOR
Intervention: Searching the Internet
Number of subjects: 22
Study: 12188443

Group type: EXPERIMENTAL
Intervention: Benzbromarone 100 mg/day
Number of subjects: 14

Group type: COMPARATOR
Intervention: Allopurinol 300 mg/day
Number of subjects: 14

Group type: COMPARATOR
Intervention: Comparison of benzbromarone to allopurinol
Number of subjects: 14
Study: 10669897

Group type: EXPERIMENTAL
Intervention: Regimen A: four tablets at 0, 8, 24 and 48 h (320 mg artemether, 1,920 mg benflumetol)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Regimen B: two tablets at 0, 8, 24 and 48 h (160 mg artemether, 960 mg benflumetol)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Regimen C: four tablets at 0, 8 and 24 h (240 mg artemether, 1,440 mg benflumetol)
Number of subjects: 39
Study: 9534283

Group type: EXPERIMENTAL
Intervention: i.v. isoproterenol infusion (low doses)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: i.v. isoproterenol infusion (higher doses)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Atropine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Peak exercise
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nocturnal sinus arrhythmia
Number of subjects: 10
Study: 1722935

Group type: EXPERIMENTAL
Intervention: barucainide (300-400 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: barucainide
Number of subjects: 10
Study: 6799558

Group type: EXPERIMENTAL
Intervention: Glucose and insulin
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Glucose, insulin and amino acids
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: TPN (Total Parenteral Nutrition)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Amino acids
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Energy supply >120-130% of daily energy output
Number of subjects: 19
Study: 30094693

Group type: EXPERIMENTAL
Intervention: weekday-on and weekend-off regimen
Number of subjects: 58

Group type: COMPARATOR
Intervention: conventional schedule
Number of subjects: 58
Study: 28236539

Group type: EXPERIMENTAL
Intervention: Internal mammary node irradiation (IMNI)
Number of subjects: 747

Group type: EXPERIMENTAL
Intervention: Standard and partial wide tangents RT techniques
Number of subjects: 747

Group type: COMPARATOR
Intervention: Arm 2 (IMNI group)
Number of subjects: 747
Study: 27052991

Group type: EXPERIMENTAL
Intervention: Lanconone® (1000 mg)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Ibuprofen (400 mg)
Number of subjects: 72
Study: 24099724

Group type: EXPERIMENTAL
Intervention: Two green kiwifruit/day plus healthy diet
Number of subjects: 85

Group type: COMPARATOR
Intervention: Healthy diet alone
Number of subjects: 85
Study: 23147979

Group type: EXPERIMENTAL
Intervention: Complementary foods in addition to breast milk from age 4 months (CF)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Exclusive breastfeeding for 6 months (EBF)
Number of subjects: 119
Study: 20335546

Group type: EXPERIMENTAL
Intervention: High-heat-treated diet
Number of subjects: 62

Group type: COMPARATOR
Intervention: Steamed diet
Number of subjects: 62
Study: 18833115

Group type: EXPERIMENTAL
Intervention: Stalevo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy with additional dosage of levodopa/DDC inhibitor
Number of subjects: 0
Study: 15684256

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) injections (40,000 UI/week subcutaneously until Ht of 40%)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Autologous blood donation (ABD) (RBC pack collected weekly as long as Ht was above 33%)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Comparison of RBC production
Number of subjects: 93
Study: 15114293

Group type: EXPERIMENTAL
Intervention: i.v. Dextran-40 infusion (Group I, n = 48)
Number of subjects: 69

Group type: COMPARATOR
Intervention: i.v. albumin infusion (Group II, n = 48)
Number of subjects: 69
Study: 10798009

Group type: EXPERIMENTAL
Intervention: pH measurement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Specific gravity measurement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sugar excretion measurement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Protein profile on SDS-PAGE
Number of subjects: 0
Study: 7597269

Group type: EXPERIMENTAL
Intervention: Regular inhaled fenoterol and ipratropium bromide by metered dose inhaler (MDI) and large volume spacer
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Regular nebulized salbutamol and ipratropium bromide
Number of subjects: 57

Group type: COMPARATOR
Intervention: Bronchodilator therapy
Number of subjects: 57
Study: 2035777

Group type: EXPERIMENTAL
Intervention: 25 micrograms of fentanyl administered prophylactically by the epidural route
Number of subjects: 0
Study: 7369086

Group type: EXPERIMENTAL
Intervention: Sensorimotor training (10 hours)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Verbal body-part identification training (10 hours)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 24
Study: 31721905

Group type: EXPERIMENTAL
Intervention: Topical 5% compound lidocaine cream (0.2 g/cm2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Morphine group (10 mg tablet)
Number of subjects: 60
Study: 27957595

Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (RME)
Number of subjects: 28
Study: 25472578

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 993

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 993
Study: 23429575

Group type: EXPERIMENTAL
Intervention: Combined optical and atropine treatment (COAT)
Number of subjects: 5
Study: 21829015

Group type: EXPERIMENTAL
Intervention: Heparin 1,000 U/ml (group 2)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Heparin 5,000 U/ml (group 1)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Both groups (1,000 U/ml and 5,000 U/ml)
Number of subjects: 184
Study: 19409095

Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention (computer-generated feedback, educational outreach, and dedicated support)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Computer-generated feedback (simple feedback)
Number of subjects: 72
Study: 17728047

Group type: EXPERIMENTAL
Intervention: Cortisol administration (50 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 15170922

Group type: EXPERIMENTAL
Intervention: Anakinra 75 mg/day
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Anakinra 150 mg/day
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Anakinra (all dosages)
Number of subjects: 472

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 472
Study: 11720073

Group type: EXPERIMENTAL
Intervention: Baby wipes
Number of subjects: 162

Group type: COMPARATOR
Intervention: Water and cleansing material
Number of subjects: 162
Study: 9734541

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 8069884

Group type: EXPERIMENTAL
Intervention: Calcium carbonate-based toothpaste with 0.3% triclosan
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Calcium carbonate-based toothpaste without triclosan
Number of subjects: 20

Group type: COMPARATOR
Intervention: Alumina-based toothpaste
Number of subjects: 20

Group type: COMPARATOR
Intervention: Silica-based toothpaste
Number of subjects: 20
Study: 1975426

Group type: EXPERIMENTAL
Intervention: 30 mg of pentamidine every two weeks
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: 150 mg of pentamidine every two weeks
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: 300 mg of pentamidine every four weeks
Number of subjects: 408

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 408
Study: 159510

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (40 microgram) administered as two puffs from a metered dose inhaler four times a day for one week (regular use)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Single dose of ipratropium bromide (40 microgram) given 2.5 hours before the test
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (propellants only) administered four times a day for one week (regular use)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control period with no treatment
Number of subjects: 12
Study: 31684916

Group type: EXPERIMENTAL
Intervention: Standardized assessment and evaluation protocol for HA implementation
Number of subjects: 241

Group type: COMPARATOR
Intervention: Ordinary routines applied in control group
Number of subjects: 241
Study: 27676226

Group type: EXPERIMENTAL
Intervention: Lung transplant recipients requiring reintubation
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Lung transplant recipients discharged to care facilities
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Lung transplant recipients overall
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Lung transplant recipients with lower capacity to engage in self-care
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Lung transplant recipients older age
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Lung transplant recipients returning to the intensive care unit
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Thirty-day readmission
Number of subjects: 201
Study: 25554797

Group type: EXPERIMENTAL
Intervention: Exercise before breakfast (AM)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Exercise after lunch (PM)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Two sessions of exercise (AM/PM)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (sedentary day)
Number of subjects: 9
Study: 24018221

Group type: EXPERIMENTAL
Intervention: Intervention sessions for alcohol use
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Abstinence goal
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Moderation goal
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Concern of relatives, friends, or doctors
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intensive care patients
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Follow-up goal change
Number of subjects: 120
Study: 21400652

Group type: EXPERIMENTAL
Intervention: Biodegradable polymer (BP) sirolimus‐eluting stent
Number of subjects: 2016

Group type: COMPARATOR
Intervention: Permanent polymer (PP) sirolimus/everolimus‐eluting stent
Number of subjects: 2016
Study: 19360536

Group type: EXPERIMENTAL
Intervention: Midwestern Prevention Project (MPP) program
Number of subjects: 961

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 961
Study: 17597038

Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Papaverine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 100
Study: 15074013

Group type: EXPERIMENTAL
Intervention: Immunosuppressive regimen after surgery (n = 16)
Number of subjects: 29

Group type: COMPARATOR
Intervention: No immunosuppression (n = 13)
Number of subjects: 29
Study: 11563899

Group type: EXPERIMENTAL
Intervention: Mesoglycan, 30 mg/day intramuscularly for 3 weeks followed by 100 mg/day orally, as an adjunct to compression therapy and topical wound care.
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo, as an adjunct to compression therapy and topical wound care.
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Mesoglycan
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study: 9758288

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg twice daily for 5 days with 200 mg trovafloxacin once daily from day 3-5
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo for 5 days with 200 mg trovafloxacin once daily from day 3-5
Number of subjects: 12
Study: 7823272

Group type: EXPERIMENTAL
Intervention: Local application of metronidazole gel
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no metronidazole application)
Number of subjects: 12
Study: 3245293

Group type: EXPERIMENTAL
Intervention: Oral cholera vaccine (3 administrations of microgranules)
Number of subjects: 18
Study: 31538954

Group type: EXPERIMENTAL
Intervention: Parent-reported child height
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Parent-reported child weight
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Calculated body mass index from parent-reported data
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Parent-reported child height and weight accuracy at baseline
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Parent-reported child height and weight accuracy after 12-week intervention
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Interrater agreement of child body mass index category
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Weight category accuracy from parent-reported data
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Parental age influence on reporting accuracy
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Child age influence on reporting accuracy
Number of subjects: 42
Study: 28734705

Group type: EXPERIMENTAL
Intervention: Proficiency based Stepwise Endovascular Curricular Training (PROSPECT)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: E-learning and simulation training (PROSPECT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: E-learning only
Number of subjects: 32

Group type: COMPARATOR
Intervention: Traditional education (Control)
Number of subjects: 32
Study: 25447334

Group type: EXPERIMENTAL
Intervention: Minding Health
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Healthy Weight
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control (obesity education video)
Number of subjects: 148
Study: 22743161

Group type: EXPERIMENTAL
Intervention: Persistent drug users (used illicit drugs other than marijuana and/or nonmedical prescription drugs every year during the first four years)
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Persistent drug users and infrequent marijuana users
Number of subjects: 620

Group type: COMPARATOR
Intervention: Employed full-time individuals
Number of subjects: 620

Group type: COMPARATOR
Intervention: Employed part-time individuals
Number of subjects: 620
Study: 21784403

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding
Number of subjects: 947

Group type: COMPARATOR
Intervention: Nonexclusive breastfeeding
Number of subjects: 947

Group type: EXPERIMENTAL
Intervention: CD4 count less than 200 cells/μL
Number of subjects: 947
Study: 19336807

Group type: EXPERIMENTAL
Intervention: Cruciate-retaining total knee replacement
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Posterior-stabilised total knee replacement
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both types of prosthetic knee with reduced patellofemoral joint
Number of subjects: 40
Study: 16951850

Group type: EXPERIMENTAL
Intervention: Acupuncture (ACP) at a point 6.5 cm above the apex of the auditory pavilion in the parietal region
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group acupuncture at a point 3 cm above the ACP point
Number of subjects: 76
Study: 14675304

Group type: EXPERIMENTAL
Intervention: Nursing interventions (specific details not provided)
Number of subjects: 47
Study: 10780758

Group type: EXPERIMENTAL
Intervention: CPAP treatment for 1 year
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 80
Study: 9351712

Group type: EXPERIMENTAL
Intervention: Continuous arteriovenous rewarming (CAVR)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Standard rewarming (SR)
Number of subjects: 57
Study: 8454808

Group type: EXPERIMENTAL
Intervention: Weight reduction
Number of subjects: 878

Group type: EXPERIMENTAL
Intervention: Na/K intervention
Number of subjects: 878

Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 878
Study: 3022785

Group type: EXPERIMENTAL
Intervention: Interferon (topically applied in a gel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interferon
Number of subjects: 0
Study: 31981832

Group type: EXPERIMENTAL
Intervention: Active video games (AVGs)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Therapeutic exercise
Number of subjects: 80
Study: 29953567

Group type: EXPERIMENTAL
Intervention: Adhesive 1
Number of subjects: 48

Group type: COMPARATOR
Intervention: Positive control (commercially available denture adhesive cream)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Adhesive 2
Number of subjects: 48
Study: 27377292

Group type: EXPERIMENTAL
Intervention: Supervised training group (STG)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Home training group (HTG)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All groups (STG, HTG, CG)
Number of subjects: 45
Study: 24141036

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg subcutaneously every 6 months
Number of subjects: 870

Group type: COMPARATOR
Intervention: Risedronate 150 mg orally every month
Number of subjects: 870

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 870

Group type: COMPARATOR
Intervention: Risedronate
Number of subjects: 870
Study: 22301925

Group type: EXPERIMENTAL
Intervention: Soy foods with high-normal isoflavones (73 mg/d)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Soy foods with low isoflavones (10 mg/d)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Soy foods with prebiotic (10 g polyfructans/d)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Soy foods with low-carbohydrate diet (26% carbohydrate)
Number of subjects: 85
Study: 21211262

Group type: EXPERIMENTAL
Intervention: Intravesical instillation of high‐dose pirarubicin during perioperative period
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intravesical perfusion of pirarubicin performed regularly after operation
Number of subjects: 120
Study: 18942602

Group type: EXPERIMENTAL
Intervention: Mechanical technique (rubber cup attached to a low-speed handpiece)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Manual technique (plastic spatula)
Number of subjects: 10
Study: 15611864

Group type: EXPERIMENTAL
Intervention: Locked intramedullary nailing
Number of subjects: 78

Group type: COMPARATOR
Intervention: External fixation
Number of subjects: 78
Study: 12796358

Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 1106

Group type: COMPARATOR
Intervention: IFN-alpha/cytarabine
Number of subjects: 1106
Study: 10555025

Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Risedronate 2.5 mg
Number of subjects: 224

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study: 8934458

Group type: EXPERIMENTAL
Intervention: Item method of directed forgetting
Number of subjects: 0

Group type: COMPARATOR
Intervention: List method of directed forgetting
Number of subjects: 0
Study: 1653142

Group type: EXPERIMENTAL
Intervention: Sumatriptan (100-300 mg oral)
Number of subjects: 5863

Group type: EXPERIMENTAL
Intervention: Sumatriptan (4-8 mg subcutaneous)
Number of subjects: 5863

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5863
Study: 6136437

Group type: EXPERIMENTAL
Intervention: Long-acting vaginal pessary containing 3.0 mg 15-methyl-PGF2(α) methyl ester
Number of subjects: 1147

Group type: COMPARATOR
Intervention: Intraamniotic administration of 2.5 mg 15-methyl-PGF2(α)
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: Long-acting vaginal pessary complemented with intramuscular injections of 15-methyl-PGF2(α) (0.2-0.4 mg every third hour for up to 12 hours)
Number of subjects: 1147

Group type: COMPARATOR
Intervention: Intraamniotic administration of 15-methyl-PGF2(α)
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: Long-acting pessary
Number of subjects: 1147
Study: 31418607

Group type: EXPERIMENTAL
Intervention: Abstinence message
Number of subjects: 388

Group type: COMPARATOR
Intervention: Harm reduction message
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Reactance (negative cognitive appraisal)
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Reactance (anger)
Number of subjects: 388